<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">33069387</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>05</Month>
        <Day>14</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>01</Month>
        <Day>31</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1578-8989</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>156</Volume>
            <Issue>4</Issue>
            <PubDate>
              <Year>2021</Year>
              <Month>Feb</Month>
              <Day>26</Day>
            </PubDate>
          </JournalIssue>
          <Title>Medicina clinica</Title>
          <ISOAbbreviation>Med Clin (Barc)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Treatment of Graves' ophthalmopathy.</ArticleTitle>
        <Pagination>
          <StartPage>180</StartPage>
          <EndPage>186</EndPage>
          <MedlinePgn>180-186</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.medcli.2020.07.031</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S0025-7753(20)30648-5</ELocationID>
        <Abstract>
          <AbstractText>Graves' ophthalmopathy is an inflammatory disease with primary involvement of the extraocular muscles and the orbit. It encompasses the most common extra-thyroid manifestation in patients with Graves-Basedow disease. The underlying cause is molecular mimicry with the TSH receptor in ocular fibroblasts, leading to an immuno-mediated pathogenesis. Glucocorticoids at high doses are the cornerstone in moderate-severe cases. However, some patients are corticorresistant or intolerant. In recent years, therapeutic novelties have been described in terms of the dosage of the immunosuppressive treatments used, as well as the emergence of biological therapy in this field. The objective of this review is to update the treatment of Graves' ophthalmopathy, as well as to present alternative options in patients resistant or intolerant to glucocorticoids.</AbstractText>
          <CopyrightInformation>Copyright © 2020 Elsevier España, S.L.U. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>González-García</LastName>
            <ForeName>Andrés</ForeName>
            <Initials>A</Initials>
            <AffiliationInfo>
              <Affiliation>Unidad de Enfermedades Sistémicas Autoinmunes y Minoritarias, Servicio de Medicina Interna, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, España. Electronic address: andres.gonzalez@salud.madrid.org.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sales-Sanz</LastName>
            <ForeName>Marco</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>CSUR de tumores orbitarios y cirugía de descompresión orbitaria en Oftalmopatía Tiroidea. Servicio de Oftalmología, Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, España.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <Language>spa</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <VernacularTitle>Tratamiento de la oftalmopatía de Graves.</VernacularTitle>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>14</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Spain</Country>
        <MedlineTA>Med Clin (Barc)</MedlineTA>
        <NlmUniqueID>0376377</NlmUniqueID>
        <ISSNLinking>0025-7753</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <CommentsCorrectionsList>
        <CommentsCorrections RefType="CommentIn">
          <RefSource>Med Clin (Barc). 2022 Jan 21;158(2):93</RefSource>
          <PMID Version="1">34144800</PMID>
        </CommentsCorrections>
      </CommentsCorrectionsList>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006111" MajorTopicYN="Y">Graves Disease</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049970" MajorTopicYN="Y">Graves Ophthalmopathy</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName>
          <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009915" MajorTopicYN="N">Orbit</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="Y">Enfermedad de Graves-Basedow</Keyword>
        <Keyword MajorTopicYN="Y">Glucocorticoides</Keyword>
        <Keyword MajorTopicYN="Y">Glucocorticoids</Keyword>
        <Keyword MajorTopicYN="Y">Graves-Basedow disease</Keyword>
        <Keyword MajorTopicYN="Y">Graves’ ophthalmopathy</Keyword>
        <Keyword MajorTopicYN="Y">Inflamación orbitaria</Keyword>
        <Keyword MajorTopicYN="Y">Orbitopathy</Keyword>
        <Keyword MajorTopicYN="Y">Orbitopatía</Keyword>
        <Keyword MajorTopicYN="Y">Rituximab</Keyword>
        <Keyword MajorTopicYN="Y">Teprotumumab</Keyword>
        <Keyword MajorTopicYN="Y">Tocilizumab</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2020</Year>
          <Month>5</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>7</Month>
          <Day>13</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>19</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>5</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>18</Day>
          <Hour>20</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33069387</ArticleId>
        <ArticleId IdType="doi">10.1016/j.medcli.2020.07.031</ArticleId>
        <ArticleId IdType="pii">S0025-7753(20)30648-5</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
